Completed PHASE3 INTERVENTIONAL 4-arm NCT01838902

Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers (PRINOGAM)

Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The Gambia

Sponsor: London School of Hygiene and Tropical Medicine

Conditions Malaria

Interventions DHA-PPQ PQ (0.2) PQ (0.4) PQ (0.75)

Updated 7 times since 2017 Last updated: Mar 20, 2018 Started: Aug 31, 2013 Primary completion: Feb 28, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Malaria, this trial is completed. The trial is conducted by London School of Hygiene and Tropical Medicine and has accumulated 7 data snapshots since 2013. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Apr 2018 [monthly]

Completed PHASE3

First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

London School of Hygiene and Tropical Medicine

Data source: London School of Hygiene and Tropical Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fajara, The Gambia